Report Overview
Global Direct Oral Anticoagulants (DOACs) Market size is expected to be worth around US$ 96.5 Billion by 2034 from US$ 44.3 Billion in 2024, growing at a CAGR of 8.1% during the forecast period 2025 to 2034.
The Direct Oral Anticoagulants (DOACs) Market is experiencing significant growth, driven by the increasing prevalence of atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism (PE), and other thromboembolic disorders worldwide. DOACs have become a preferred alternative to traditional anticoagulants due to their predictable anticoagulant effects, fixed dosing regimens, reduced need for routine coagulation monitoring, and lower risk of certain bleeding complications.
Rising awareness of cardiovascular disease prevention, an aging global population, and the growing burden of chronic conditions are contributing to increased adoption of these therapies. Continuous advancements in pharmaceutical research, expanding clinical evidence supporting the safety and efficacy of DOACs, and updated treatment guidelines are further strengthening market demand. Healthcare providers are increasingly prescribing oral factor Xa inhibitors and direct thrombin inhibitors to improve patient outcomes and treatment adherence.
North America remains the leading regional market, supported by advanced healthcare infrastructure, favorable reimbursement policies, and high adoption of innovative anticoagulant therapies. Meanwhile, the Asia-Pacific region is expected to witness robust growth due to improving healthcare access, increasing cardiovascular disease incidence, and rising healthcare expenditure. Ongoing research, product innovation, and expanding access to advanced anticoagulant therapies are expected to support sustained market expansion throughout the forecast period.
*Click here for more information: https://market.us/report/direct-oral-anticoagulants-doacs-market/
*
Key Takeaways
- The Direct Oral Anticoagulants Market was valued at US$ 44.3 billion in 2024 and is projected to reach US$ 96.5 billion by 2034, expanding at a CAGR of 8.1% during the forecast period.
- By product type, the market is segmented into oral factor Xa inhibitors and direct thrombin inhibitors. The oral factor Xa inhibitors segment dominated the market in 2023, accounting for 70.3% of the total market share.
- Based on application, the market is categorized into atrial fibrillation, deep vein thrombosis, and other applications. Among these, the atrial fibrillation segment held the largest share of 61.2% in 2023.
- North America emerged as the leading regional market, holding the largest market share in 2023.
Key Market Segments
- By Product Type
- Oral Factor Xa Inhibitors
- Direct Thrombin Inhibitors
- By Application
- Atrial Fibrillation
- Deep Vein Thrombosis
- Othes
Market Key Players
- Viatris
- Sandoz
- GlaxoSmithKline
- Daiichi Sankyo
- Bristol Myers Squibb Co
- Bayer AG
- Anthos Therapeutics
- Accord Healthcare
Market Dynamics
Driver
The increasing prevalence of cardiovascular diseases and thromboembolic disorders is a major driver of the Direct Oral Anticoagulants (DOACs) Market. DOACs are widely prescribed to prevent stroke in patients with non-valvular atrial fibrillation and to treat or prevent deep vein thrombosis (DVT) and pulmonary embolism (PE). According to the World Health Organization (WHO), cardiovascular diseases cause approximately 17.9 million deaths each year, making them the leading cause of mortality worldwide.
The U.S. Centers for Disease Control and Prevention (CDC) reports that about 805,000 people experience a heart attack annually in the United States, while the CDC estimates that around 900,000 people are affected by venous thromboembolism (VTE), including DVT and PE, each year, resulting in up to 100,000 premature deaths. The growing elderly population, increasing obesity, diabetes, hypertension, and sedentary lifestyles are contributing to higher anticoagulant demand. DOACs offer fixed dosing, fewer food and drug interactions, and reduced monitoring requirements compared with vitamin K antagonists, supporting broader clinical adoption and improved patient adherence across healthcare systems.
Trend
A significant trend in the Direct Oral Anticoagulants (DOACs) Market is the increasing inclusion of DOACs in international clinical practice guidelines and their growing use as first-line therapy for eligible patients with atrial fibrillation and venous thromboembolism. Organizations such as the European Society of Cardiology (ESC), the American College of Cardiology (ACC), and the American Heart Association (AHA) increasingly recommend DOACs over warfarin for many patients because of their favorable safety profile and ease of use.
According to the CDC, approximately 12.1 million people in the United States are projected to have atrial fibrillation by 2030, highlighting the expanding patient population requiring anticoagulation therapy. In addition, healthcare systems are adopting electronic prescribing, clinical decision support tools, and digital patient monitoring to improve medication adherence and reduce complications. Pharmaceutical manufacturers continue to generate real-world evidence supporting the effectiveness of DOACs in diverse patient populations. These developments are strengthening physician confidence and encouraging greater use of oral anticoagulants in routine cardiovascular care worldwide.
Restraint
Despite their clinical advantages, the Direct Oral Anticoagulants (DOACs) Market faces restraints related to bleeding risks, treatment costs, and patient-specific clinical considerations. Although DOACs generally demonstrate lower rates of certain major bleeding events than warfarin, serious bleeding complications remain a concern, particularly among elderly patients and those with kidney impairment. The U.S. National Institutes of Health (NIH) notes that anticoagulant therapy requires careful patient assessment because bleeding remains the most significant adverse effect.
Some patients with mechanical heart valves or moderate-to-severe mitral stenosis are not suitable candidates for DOAC therapy, limiting their use in specific clinical settings. Furthermore, the relatively higher cost of DOACs compared with generic vitamin K antagonists can affect affordability in countries with limited reimbursement coverage. In low- and middle-income regions, healthcare systems may continue to rely on less expensive anticoagulants despite the convenience of DOACs. These clinical and economic challenges may slow market penetration, particularly where healthcare budgets and patient access remain constrained.
Opportunity
The aging global population and continued expansion of cardiovascular healthcare services present significant opportunities for the Direct Oral Anticoagulants (DOACs) Market. According to the World Health Organization (WHO), one in six people worldwide will be aged 60 years or older by 2030, increasing from 1 billion in 2020 to 1.4 billion by 2030. Older adults have a substantially higher risk of atrial fibrillation, stroke, and venous thromboembolism, creating sustained demand for effective anticoagulation therapies. Governments are also strengthening cardiovascular disease prevention strategies, expanding access to diagnostic services, and improving chronic disease management through primary healthcare programs.
Advances in reversal agents, expanded indications supported by clinical research, and broader reimbursement coverage are expected to improve confidence in DOAC therapy. Emerging economies are investing in healthcare infrastructure, specialist cardiac care, and pharmaceutical access, allowing more patients to receive evidence-based anticoagulant treatment. These developments, combined with increasing physician awareness and ongoing therapeutic innovation, are expected to create long-term growth opportunities for DOAC manufacturers and healthcare providers worldwide.
Conclusion
The global Direct Oral Anticoagulants (DOACs) Market is poised for sustained growth, driven by the rising prevalence of atrial fibrillation, deep vein thrombosis, pulmonary embolism, and other cardiovascular disorders. The market is projected to grow from US$ 44.3 billion in 2024 to US$ 96.5 billion by 2034, registering a CAGR of 8.1% during the forecast period. Increasing adoption of oral factor Xa inhibitors, expanding clinical guideline recommendations, and growing preference for anticoagulants with predictable efficacy and reduced monitoring requirements are supporting market expansion.
Continued advancements in cardiovascular care, improved healthcare infrastructure, and broader access to innovative therapies are expected to further strengthen demand. Although challenges such as bleeding risks, treatment costs, and reimbursement variations remain, ongoing pharmaceutical innovation, an aging global population, and increasing awareness of thromboembolic disease management will continue to create growth opportunities. As healthcare systems increasingly prioritize effective stroke prevention and evidence-based anticoagulation therapies, the DOACs market is expected to maintain strong long-term growth across both developed and emerging regions.
Top comments (0)